GliaSite Brachytherapy for Treatment of Recurrent Malignant Gliomas: A Retrospective Multi-institutional Analysis
Authors:
- Sylvan B. GreenSGSylvan B. Green
- Abhay SananASAbhay Sanan
- Joseph JenretteJJJoseph Jenrette
- Christopher SchultzCSChristopher Schultz
- Michael PapagikosMPMichael Papagikos
- Stephen P. TatterSTStephen P. Tatter
- Ashish PatelAPAshish Patel
- Pradip AminPAPradip Amin
- Robert LustigRLRobert Lustig
- Kenneth T. BastinKBKenneth T. Bastin
- Gordon WatsonGWGordon Watson
- 1 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 58 (4) , 701-709
Abstract
To review the cumulative experience of 10 institutions in treating recurrent malignant gliomas with the brachytherapy device, GliaSite Radiation Therapy System. The patient population consisted of 95 patients with recurrent grade 3 or 4 gliomas, a median age of 51 years, and a median Karnofsky performance status score of 80. All patients had previously undergone resection and had received external beam radiotherapy as part of their initial treatment. After recurrence, each patient underwent maximal surgical debulking of their recurrent lesion and placement of an expandable balloon catheter (GliaSite) in the tumor cavity. The balloon was afterloaded with liquid I (Iotrex) to deliver a median dose of 60 Gy to an average depth of 1 cm with a median dose rate of 52.3 Gy/hr. Patients were carefully followed with serial magnetic resonance imaging and monthly examinations for tumor progression, side effects, and survival. The median survival for all patients, measured from date of GliaSite placement, was 36.3 weeks with an estimated 1 year survival of 31.1%. The median survival was 35.9 weeks for patients with an initial diagnosis of glioblastoma multiforme and 43.6 weeks for those with non- glioblastoma multiforme malignant gliomas. Analysis of the influence of various individual prognostic factors on patient survival demonstrated that only Karnofsky performance status significantly predicted for improved survival. There were three cases of pathologically documented radiation necrosis. Reirradiation of malignant gliomas with the GliaSite Radiation Therapy System after reresection seems to provide a modest survival benefit above what would be expected from surgery alone. This report not only confirms the initial results of the feasibility study but provides evidence that similar outcomes can be obtained outside of a clinical trial.Keywords
This publication has 31 references indexed in Scilit:
- The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and CarmustineNeurosurgery, 2002
- The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and CarmustineNeurosurgery, 2002
- On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate125I implants in ?failed? and ?newly diagnosed? glioblastoma patients: Quality assurance methodology and a possible future adjuvant for therapeutic enhancementJournal of Neuro-Oncology, 1995
- Comparison of Stereotactic Radiosurgery and Brachytherapy in the Treatment of Recurrent Glioblastoma MultiformeNeurosurgery, 1995
- Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomasCancer, 1994
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI: Journal of the National Cancer Institute, 1993
- Reoperation for glioblastomaJournal of Neurosurgery, 1981
- Interstitial Irradiation of Brain TumorsNeurosurgery, 1981
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980
- Extreme Hypoxia; its Effect on the Survival of Mammalian Cells Irradiated at High and Low Dose-ratesBritish Journal of Radiology, 1966